Previous 10 | Next 10 |
ADC Therapeutics (ADCT): Q4 GAAP EPS of -$0.73.Cash and cash equivalents were $439.2 million as of December 31, 2020, compared to $115.6 million as of December 31, 2019.Press Release For further details see: ADC Therapeutics reports Q4 results
- Lonca BLA accepted by FDA with priority review; PDUFA date May 21, 2021 - Commercial, medical affairs, CMC and support functions prepared for potential Lonca approval - Updated data for lead programs Lonca and Cami presented at American Society of Hematology (ASH) An...
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced th...
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today tha...
Interim results anticipated in the first half of 2021 ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients wit...
Late-stage biotechnology company ADC Therapeutics ([[ADCT]] +2.5%) announces initiation of an expanded access program ((EAP)) for loncastuximab tesirine ((Lonca, formerly ADCT-402)) for patients in the U.S. with relapsed or refractory diffuse large B-cell lymphoma ((DLBCL)...
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today the...
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today tha...
Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie. Legend Biotech was cleared to start a US Phase I trial...
ADC Therapeutics ([[ADCT]] +0.6%) has entered into an agreement to jointly form a new company, Overland ADCT BioPharma Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital.Overland Pharmaceuticals to have a 51% stake and ADC Therapeu...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...